Last updated on February 2018

Evaluation of the Effectiveness and Quality of Life With the Administration of the Fixed Combination of Budesonide Formoterol in Greek Patients With Asthma During Routine Clinical Practice.


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Asthma | Quality of life
  • Age: Between 18 - 80 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Male and Female
  • Patients about to start treatment with the inhaled combination of budesonide and formoterol fumarate dihydrate at doses 100 / 6mcg, 200 / 6mcg, 400/12 mcg, through Elpenhlaler device
  • Regular treatment of asthma, wherein the administration of the combination (inhaled corticosteroid and long-action beta2-agonist) is appropriate
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled beta2-agonists short-acting
  • Patients who signed Informed Consent Patients eligible to follow the study procedures

Exclusion Criteria:

  • Patients who will be treated out of SpC
  • Patients without Informed Consent
  • Patients not eligible to follow the study procedures

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.